{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:59:58Z","timestamp":1790513998044,"version":"4.1.0"},"reference-count":48,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":110,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100006280","name":"\u2018Ministerio de Ciencia y Tecnolog\u00eda\u2019","doi-asserted-by":"crossref","award":["SAF-26091-2011"],"award-info":[{"award-number":["SAF-26091-2011"]}],"id":[{"id":"10.13039\/501100006280","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Cachexia, Sarcopenia and Muscle"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1002\/jcsm.12035","type":"journal-article","created":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T09:25:48Z","timestamp":1431595548000},"page":"48-59","source":"Crossref","is-referenced-by-count":48,"title":["A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy"],"prefix":"10.1002","volume":"7","author":[{"given":"M\u00edriam","family":"Toledo","sequence":"first","affiliation":[{"name":"Cancer Research Group, Departament de Bioqu\u00edmica i Biologia Molecular, Facultat de Biologia; Universitat de Barcelona; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Penna","sequence":"additional","affiliation":[{"name":"Cancer Research Group, Departament de Bioqu\u00edmica i Biologia Molecular, Facultat de Biologia; Universitat de Barcelona; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Oliva","sequence":"additional","affiliation":[{"name":"Departament d'Estad\u00edstica, Facultat de Biologia; Universitat de Barcelona; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Luque","sequence":"additional","affiliation":[{"name":"Cancer Research Group, Departament de Bioqu\u00edmica i Biologia Molecular, Facultat de Biologia; Universitat de Barcelona; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Betancourt","sequence":"additional","affiliation":[{"name":"Cancer Research Group, Departament de Bioqu\u00edmica i Biologia Molecular, Facultat de Biologia; Universitat de Barcelona; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Marmonti","sequence":"additional","affiliation":[{"name":"Cancer Research Group, Departament de Bioqu\u00edmica i Biologia Molecular, Facultat de Biologia; Universitat de Barcelona; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"L\u00f3pez-Soriano","sequence":"additional","affiliation":[{"name":"Cancer Research Group, Departament de Bioqu\u00edmica i Biologia Molecular, Facultat de Biologia; Universitat de Barcelona; Barcelona Spain"},{"name":"Institut de Biomedicina de la Universitat de Barcelona; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Argil\u00e9s","sequence":"additional","affiliation":[{"name":"Cancer Research Group, Departament de Bioqu\u00edmica i Biologia Molecular, Facultat de Biologia; Universitat de Barcelona; Barcelona Spain"},{"name":"Institut de Biomedicina de la Universitat de Barcelona; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00edlvia","family":"Busquets","sequence":"additional","affiliation":[{"name":"Cancer Research Group, Departament de Bioqu\u00edmica i Biologia Molecular, Facultat de Biologia; Universitat de Barcelona; Barcelona Spain"},{"name":"Institut de Biomedicina de la Universitat de Barcelona; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,5,14]]},"reference":[{"key":"10.1002\/jcsm.12035-BIB0001|jcsm12035-cit-0001","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/canjclin.57.4.225","article-title":"The lethal phenotype of cancer: the molecular basis of death due to malignancy","volume":"57","author":"Loberg","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1002\/jcsm.12035-BIB0002|jcsm12035-cit-0002","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/sj.bjc.6601620","article-title":"Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids","volume":"90","author":"Moses","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1002\/jcsm.12035-BIB0003|jcsm12035-cit-0003","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","article-title":"Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group","volume":"69","author":"Dewys","year":"1980","journal-title":"Am J Med"},{"key":"10.1002\/jcsm.12035-BIB0004|jcsm12035-cit-0004","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clnu.2009.12.004","article-title":"Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) \u201ccachexia-anorexia in chronic wasting diseases\u201d and \u201cnutrition in geriatrics\u201d","volume":"29","author":"Muscaritoli","year":"2010","journal-title":"Clin Nutr"},{"key":"10.1002\/jcsm.12035-BIB0005|jcsm12035-cit-0005","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin Nutr"},{"key":"10.1002\/jcsm.12035-BIB0006|jcsm12035-cit-0006","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/ajcn\/84.3.475","article-title":"The underappreciated role of muscle in health and disease","volume":"84","author":"Wolfe","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"10.1002\/jcsm.12035-BIB0007|jcsm12035-cit-0007","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ygyno.2011.12.435","article-title":"A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life","volume":"124","author":"Macci\u00f2","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1002\/jcsm.12035-BIB0008|jcsm12035-cit-0008","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/1471-2407-11-493","article-title":"A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients-ACCeRT study","volume":"11","author":"Rogers","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1002\/jcsm.12035-BIB0009|jcsm12035-cit-0009","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s13539-014-0149-7","article-title":"Are we closer to having drugs to treat muscle wasting disease?","volume":"5","author":"Morley","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12035-BIB0010|jcsm12035-cit-0010","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","article-title":"Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment","volume":"15","author":"Prado","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1002\/jcsm.12035-BIB0011|jcsm12035-cit-0011","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","article-title":"Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity","volume":"13","author":"Prado","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1002\/jcsm.12035-BIB0012|jcsm12035-cit-0012","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1200\/JCO.2009.24.9730","article-title":"Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study","volume":"28","author":"Antoun","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1002\/jcsm.12035-BIB0013|jcsm12035-cit-0013","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1002\/jcsm.12035-BIB0014|jcsm12035-cit-0014","first-page":"408","article-title":"Sorafenib downregulates ERK\/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line","volume":"3","author":"Chai","year":"2010","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1002\/jcsm.12035-BIB0015|jcsm12035-cit-0015","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1002\/jcsm.12035-BIB0016|jcsm12035-cit-0016","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1002\/jcsm.12035-BIB0017|jcsm12035-cit-0017","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","article-title":"Sorafenib for the treatment of advanced renal cell carcinoma","volume":"12","author":"Kane","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1002\/jcsm.12035-BIB0018|jcsm12035-cit-0018","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1002\/jcsm.12035-BIB0019|jcsm12035-cit-0019","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/annonc\/mdp605","article-title":"Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma","volume":"21","author":"Antoun","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1002\/jcsm.12035-BIB0020|jcsm12035-cit-0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.critrevonc.2012.02.001","article-title":"Clinical nutrition, body composition and oncology: a critical literature review of the synergies","volume":"84","author":"Jacquelin-Ravel","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1002\/jcsm.12035-BIB0021|jcsm12035-cit-0021","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/pbc.24828","article-title":"A randomized, double-blind, placebo-controlled clinical trial of megestrol acetate as an appetite stimulant in children with weight loss due to cancer and\/or cancer therapy","volume":"61","author":"Cuvelier","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/jcsm.12035-BIB0022|jcsm12035-cit-0022","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00520-013-2081-3","article-title":"Phase I\/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy","volume":"22","author":"Greig","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1002\/jcsm.12035-BIB0023|jcsm12035-cit-0023","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004310.pub2","article-title":"Megestrol acetate for the treatment of anorexia-cachexia syndrome","author":"Berenstein","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1002\/jcsm.12035-BIB0024|jcsm12035-cit-0024","doi-asserted-by":"crossref","first-page":"636","DOI":"10.20452\/pamw.510","article-title":"Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome-a systematic review and meta-analysis","volume":"118","author":"Le\u015bniak","year":"2008","journal-title":"Pol Arch Med Wewn"},{"key":"10.1002\/jcsm.12035-BIB0025|jcsm12035-cit-0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1615\/CritRevOncog.v9.i2.10","article-title":"Cytokine involvement in cancer anorexia\/cachexia: Role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms","volume":"9","author":"Mantovani","year":"1998","journal-title":"Crit Rev Oncog"},{"key":"10.1002\/jcsm.12035-BIB0026|jcsm12035-cit-0026","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clnu.2013.01.004","article-title":"A new look at an old drug for the treatment of cancer cachexia: megestrol acetate","volume":"32","author":"Argil\u00e9s","year":"2013","journal-title":"Clin Nutr"},{"key":"10.1002\/jcsm.12035-BIB0027|jcsm12035-cit-0027","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.clnu.2010.06.003","article-title":"Megestrol acetate: its impact on muscle protein metabolism supports its use in cancer cachexia","volume":"29","author":"Busquets","year":"2010","journal-title":"Clin Nutr"},{"key":"10.1002\/jcsm.12035-BIB0028|jcsm12035-cit-0028","first-page":"e135","article-title":"Megestrol acetate treatment influences tissue amino acid uptake and incorporation during cancer cachexia","volume":"7","author":"Toledo","year":"2012","journal-title":"ESPEN J"},{"key":"10.1002\/jcsm.12035-BIB0029|jcsm12035-cit-0029","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.1158\/0008-5472.CAN-04-0425","article-title":"Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting","volume":"64","author":"Busquets","year":"2004","journal-title":"Cancer Res"},{"key":"10.1002\/jcsm.12035-BIB0030|jcsm12035-cit-0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0300-9629(92)90026-M","article-title":"Effect of clenbuterol on skeletal muscle atrophy in mice induced by the glucocorticoid dexamethasone","volume":"102","author":"Agbenyega","year":"1992","journal-title":"Comp Biochem Physiol Comp Physiol"},{"key":"10.1002\/jcsm.12035-BIB0031|jcsm12035-cit-0031","doi-asserted-by":"crossref","first-page":"R1076","DOI":"10.1152\/ajpregu.2000.279.3.R1076","article-title":"Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat","volume":"279","author":"Rajab","year":"2000","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1002\/jcsm.12035-BIB0032|jcsm12035-cit-0032","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/mus.10092","article-title":"Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor","volume":"25","author":"Hinkle","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1002\/jcsm.12035-BIB0033|jcsm12035-cit-0033","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000063712","article-title":"Muscle-specific effects of hindlimb suspension and clenbuterol in mature male rats","volume":"171","author":"Wineski","year":"2002","journal-title":"Cells Tissues Organs"},{"key":"10.1002\/jcsm.12035-BIB0034|jcsm12035-cit-0034","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1378\/chest.113.4.1095","article-title":"Long-acting inhaled beta2-agonists in asthma therapy","volume":"113","author":"Moore","year":"1998","journal-title":"Chest"},{"key":"10.1002\/jcsm.12035-BIB0035|jcsm12035-cit-0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nmd.2006.08.012","article-title":"Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue","volume":"17","author":"Harcourt","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1002\/jcsm.12035-BIB0036|jcsm12035-cit-0036","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3892\/etm.2011.260","article-title":"Formoterol and cancer muscle wasting in rats: effects on muscle force and total physical activity","volume":"2","author":"Busquets","year":"2011","journal-title":"Exp Ther Med"},{"key":"10.1002\/jcsm.12035-BIB0037|jcsm12035-cit-0037","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.clnu.2012.03.005","article-title":"l-carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer","volume":"31","author":"Busquets","year":"2012","journal-title":"Clin Nutr"},{"key":"10.1002\/jcsm.12035-BIB0038|jcsm12035-cit-0038","unstructured":"DIRECTIVE 2010\/63\/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes"},{"key":"10.1002\/jcsm.12035-BIB0039|jcsm12035-cit-0039","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0003-2697(87)90021-2","article-title":"Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction","volume":"162","author":"Chomczynski","year":"1987","journal-title":"Anal Biochem"},{"key":"10.1002\/jcsm.12035-BIB0040|jcsm12035-cit-0040","first-page":"189","article-title":"Cancer cachexia: physical activity and muscle force in tumour-bearing rats","volume":"25","author":"Toledo","year":"2011","journal-title":"Oncol Rep"},{"key":"10.1002\/jcsm.12035-BIB0041|jcsm12035-cit-0041","first-page":"1","article-title":"Mechanisms and treatment of cancer cachexia","author":"Argil\u00e9s","year":"2012","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1002\/jcsm.12035-BIB0042|jcsm12035-cit-0042","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0092-8674(04)00400-3","article-title":"Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy","volume":"117","author":"Sandri","year":"2004","journal-title":"Cell"},{"key":"10.1002\/jcsm.12035-BIB0043|jcsm12035-cit-0043","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.biocel.2005.03.010","article-title":"Ca(2+)-dependent proteolysis in muscle wasting","volume":"37","author":"Costelli","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1002\/jcsm.12035-BIB0044|jcsm12035-cit-0044","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1054\/bjoc.2001.1696","article-title":"Activation of Ca(2+)-dependent proteolysis in skeletal muscle and heart in cancer cachexia","volume":"84","author":"Costelli","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1002\/jcsm.12035-BIB0045|jcsm12035-cit-0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00000658-200101000-00003","article-title":"Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation","volume":"233","author":"Hasselgren","year":"2001","journal-title":"Ann Surg"},{"key":"10.1002\/jcsm.12035-BIB0046|jcsm12035-cit-0046","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cmet.2007.11.004","article-title":"FoxO3 coordinately activates protein degradation by the autophagic\/lysosomal and proteasomal pathways in atrophying muscle cells","volume":"6","author":"Zhao","year":"2007","journal-title":"Cell Metab"},{"key":"10.1002\/jcsm.12035-BIB0047|jcsm12035-cit-0047","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.ajpath.2012.12.023","article-title":"Autophagic degradation contributes to muscle wasting in cancer cachexia","volume":"182","author":"Penna","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1002\/jcsm.12035-BIB0048|jcsm12035-cit-0048","doi-asserted-by":"crossref","first-page":"e79603","DOI":"10.1371\/journal.pone.0079603","article-title":"Pharmacokinetics of drugs in cachectic patients: a systematic review","volume":"8","author":"Trobec","year":"2013","journal-title":"PLoS One"}],"container-title":["Journal of Cachexia, Sarcopenia and Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcsm.12035","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcsm.12035","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/jcsm.12035\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T23:51:17Z","timestamp":1748389877000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcsm.12035"}},"subtitle":["Chemotherapy and cachexia"],"short-title":[],"issued":{"date-parts":[[2015,5,14]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"URL":"https:\/\/doi.org\/10.1002\/jcsm.12035","archive":["Portico"],"relation":{},"ISSN":["2190-5991"],"issn-type":[{"value":"2190-5991","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5,14]]}}}